Djibouti
Tuberculosis profile
| High HIV burden |
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.87 (0.53–1.2) 100 (61–136)
Mortality (HIV+TB only) 0.12 (0.09–0.15) 14 (10–17)
Prevalence  (includes HIV+TB) 7.9 (4.1–13) 906 (468–1 483)
Incidence  (includes HIV+TB) 5.4 (4.8–6.1) 619 (551–697)
Incidence (HIV+TB only) 0.39 (0.33–0.44) 45 (38–51)
Case detection, all forms (%) 58 (52–66)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
29 (2–81) 47 (0–93)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 150   233
Pulmonary, clinically diagnosed 379    
Extrapulmonary 1 400    
       
Total new and relapse 3 162    
Previously treated, excluding relapses 0    
Total cases notified 3 162    
Among 1 150 new cases:
45 (4%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 449 (126%)   1 449
Laboratory-confirmed RR-/MDR-TB cases     160
Patients started on MDR-TB treatment     1
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 604 (51)
HIV-positive TB patients 121 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 94 (78)
HIV-positive TB patients on antiretroviral therapy (ART) 36 (30)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 31
Previously treated cases, excluding relapse, registered in 2012  
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 51
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 5.7
Drug susceptibility testing (per 5 million population) 5.7
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically  
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-27 Data: www.who.int/tb/data